Vitamin D Signaling Modulators in Cancer Therapy

Luo, Wei; Johnson, Candace S.; Trump, Donald L.

doi:10.1016/bs.vh.2015.11.004

Cited by 15 publications

(9 citation statements)

References 243 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive association between vitamin D and miRNAs levels in SLE patients was found to be disrupted. The cross-sectional design is a limitation and therefore we performed an invitro experiment on T cells response to vitamin D stimulation and miRNAsexpression.The results wereinaccordance with the case-control study findings and demonstrated increased expression of miRNA-377, miRNA-342, miRNA-10a, miRNA-374b, miRNA-125a, and miRNA-410 in cultured T cells from SLE patients compared with normal T cells with supplement of vitamin D.In addition, we also found activation of vitamin D signaling such as VDR, CYP24A1, and CYP27B1, which mediates most of the activities of 1α,25(OH) 2 D 3 in the T cells [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Altered microRNAs expression in T cells of patients with SLE involved in the lack of vitamin D

Yang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Vitamin D has been recognized as a potent immunomodulator and its deficiency is common in different population groups including patients with SLE. As miRNAs regulation plays a significant role in SLE, the present study aimed to evaluate the association between vitamin D status and miRNAs levels in patients with SLE. The serum concentrations of vitamin D (25-hydroxyvitamin D) and the levels of six miRNAs in T cells from patients with SLE were measured in 42 SLE cases and 48 healthy controls. Vitamin D treatment was also performed in isolated and cultured T cells from SLE patients in different times and doses. Vitamin D insufficiency (25-hydroxyvitamin D concentration <20 ng/ml) was more common in cases than in controls. Although age and BMI were similar, cases had significantly lower concentrations of miRNA-377, miRNA-342, miRNA-10a, miRNA-374b, miRNA-125a, and miRNA-410 than controls. Furthermore, a significant positive correlation was also observed between 25-hydroxyvitamin D concentrations and measured miRNAs levels. A significant difference in observed miRNAs levels was also observed in patients with 25-hydroxyvitamin D insufficiency compared with patients with 25-hydroxyvitamin D concentration ≥20 ng/ml. And 1α,25(OH)2D3 differentially regulated miRNAs expression in dose- and time- manner in vitro. Lower expressions of miRNA-377, miRNA-342, miRNA-10a, miRNA-374b, miRNA-125a, and miRNA-410 were found in SLE patients. And severe vitamin D deficiency is associated with decreased observed miRNAs levels in SLE patients. A 25-hydroxyvitamin D concentration value <20 ng/ml is suggested as the “cut-off” for such immunological alterations in patients with SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Altered microRNAs expression in T cells of patients with SLE involved in the lack of vitamin D

Yang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…This effect to reduce 27HC is in addition to the many previously described actions of vitamin D to inhibit breast cancer growth and progression [8–10, 26, 27]. Vitamin D supplements may be particularly useful for those whose breast cancer treatment includes aromatase inhibitors and who become resistant to that therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, the data in this work suggest that vitamin D supplementation may be a simple way to suppress 27HC-mediated ER stimulation in ER+ breast cancers by decreasing the 27HC concentration in the circulation. This beneficial action of vitamin D would be in addition to all of the other pathways by which vitamin D has been shown to inhibit the progression of breast cancer [8–10]. …”

Section: Discussionmentioning

confidence: 99%

“…Vitamin D is a prohormone for the steroid hormone calcitriol (1,25-dihydroxyvitamin D 3 , 1,25(OH) 2 D 3 ), which is estimated to be responsible for the transcriptional regulation of 0.5–5% of the total human genome [7], including those known to influence pathways associated with cancer growth and progression [8–10]. Calcitriol can reduce its own activation of target genes by inhibiting expression of CYP27B1 [11, 12], the enzyme responsible for 1-α-hydroxylation of 25-hydroxyvitamin D (25OHD) to form calcitriol (Fig.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial

Going

Alexandrova

Lau

et al. 2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…However, others in the field of vitamin D and cancer have suggested that the clinical trials performed so far were not performed in a manner that guarantees detection of positive effects of VDDs on cancer treatment (eg; [14-16]), and this suggests that future trials, well designed, are warranted. This seems to be particularly true regarding the use of VDDs in the treatment of Acute Myeloid Leukemia (AML).…”

Section: Introductionmentioning

confidence: 99%

BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents

Wang

Harrison

Studzinski

2017

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

Vitamin D has so far not fulfilled its early promise as an antineoplastic agent, in spite of compelling in vitro data. With the aim of bringing vitamin D or its derivatives (VDDs) effectively to the clinic, we developed a two-pronged approach. First, by adding the plant-derived Carnosic Acid (CA) to a vitamin D2 derivative Doxercalciferol we increased its differentiation potency without increasing it hypercalcemic properties. Second, we added these two agents together to AML cells already treated with Cytarabine (AraC), the standard drug for the treatment of patients with AML. We now report that BRAF, a part of the MAPK signaling pathway, is required for the optimally increased cell death in this system and acts upstream of BIM, the regulator of the caspase cascade that leads to cell death by apoptosis. It is proposed that this therapeutic regimen should be tested in a clinical trial.

show abstract

Vitamin D Signaling Modulators in Cancer Therapy

Cited by 15 publications

References 243 publications

Altered microRNAs expression in T cells of patients with SLE involved in the lack of vitamin D

Altered microRNAs expression in T cells of patients with SLE involved in the lack of vitamin D

Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial

BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents

Contact Info

Product

Resources

About